Bayer Animal Health, manufacturer of Advocate, is launching an advertising campaign to support its 'Be Lungworm Aware' initiative, which aims to educate pet owners on the spread of Angiostrongylus vasorum and encourage them to seek advice from their local veterinary practice.

The campaign will see a new TV 'public information' style advertisement targeting dog owners.  It will air on 20 national TV channels during April including ITV1, 2 and 3, Sky 1, 2 and 3, More 4 and Film4, with air time dedicated to GMTV and daytime ITV.

The TV advertising campaign will focus on the parasite's intermediate hosts - slugs and snails - and the ease in which dogs can become infected with the parasite by picking up something as simple as a toy with a slug attached to it.

Print advertisements will also be running in national newspapers and women's consumer magazines with a focus on publications read by pet owners.

Marketing support material is available for veterinary practices wishing to participate in the 'Be Lungworm Aware' initiative.  For further details, or to order the new practice materials, please contact your Bayer representative or ring 0845 2574798 quoting 'Be Lungworm Aware'.

A Royal College of Veterinary Surgeons audit panel is to visit UK veterinary schools to assess how Extra-Mural Studies (EMS) is being carried out, identify good practice and make recommendations for improvement. The exercise is part of a package of measures which aims to improve the way that EMS helps veterinary undergraduates to gain skills and knowledge in a practice environment.

RCVS Council agreed to the implementation of proposals made by a Working Party set up to review the whole EMS process in November 2009. While the EMS system was largely agreed to be valuable and working well, some areas were identified for improvement. Many of the recommendations centred on a better understanding amongst all parties involved - students, practices and vet schools - of the aims and objectives of EMS for the student, and improved communication about expectations and outcomes.

As a first step, the Education Policy and Specialisation Committee has put in place an audit of EMS at the veterinary schools. It has commissioned Dr Barry Johnson, who led the original Working Party, together with practitioners David Black, David Wadsworth and Dr Chris Chesney, to follow through individual cases, talking to the students, practitioners and clinical tutors and EMS co-ordinators at the vet schools, to build a picture of how administration, communication and follow-up is managed.

Barry said: "The objective of the audit is to identify areas of good practice that can be shared, and identify where improvements could be made - it will also promote dialogue between practices and the schools. The exercise will be repeated over the next couple of years to track changes."

The first audit took place at the Royal Veterinary College in February, as part of the full RCVS visitation of the undergraduate degree programme. The EMS audit panel will report its initial findings in June.

The full report and recommendations from the EMS Working Party can be viewed at www.rcvs.org.uk/EMS.

US company Midmark is running a UK prize draw to win a Cardell 9401 blood pressure monitor worth nearly £2000.

To enter the draw, click here.

Dogs Trust has come out firmly against RSPCA-supported proposals to re-introduce the dog licence.

The dog welfare charity says it does not believe re-introducing the dog licence would provide a welfare benefit for dogs. It has also expressed surprise at the RSPCA position, which is that: "a licence would be hugely beneficial in addressing many animal welfare concerns stemming from overbreeding of dogs to a lack of traceable ownership." Dogs Trust has said this view is extremely naïve, that responsible owners might struggle to pay what is likely to be a punitive annual licence, and that a licence is simply a tax on dog ownership. 

Meanwhile, the RSPCA has announced the results of a survey in which 2 out of 3 pet owners said they would be in favour of a licence scheme. 76% said that a dog licence should be enforced in England to help curb problems such as 'puppy farms', stray dogs, stolen dogs and animal abandonments.

The RSPCA also says that research carried out on its behalf by Reading University clearly shows that an affordable and well-enforced dog licensing scheme could provide funding for a range of issues, most of which are currently funded poorly by central and local government. Professor Emeritus Martin Upton from Reading University's school of agriculture, policy and development, said: "Our study into the potential costs and benefits of dog licencing and registration found that such a scheme could greatly contribute to responsible dog ownership and animal welfare."

Dogs Trust says the dog licence has been shown to be an ineffective measure in the UK. In Northern Ireland, where the dog licence is still a requirement, only an estimated one-third of all dog owners currently have their dogs licensed. Northern Ireland still has the highest number of stray dogs per head of population of any region in the UK and the number of dogs put to sleep in the region represents a staggering 34% of the total UK figure.

The charity recommends compulsory microchipping as the most effective means of registration as well as identification of a dog. Unlike the dog licence, which involves an annual fee, microchipping involves just a small one-off fee (Dogs Trust offers microchipping at its centres for £10).  The benefit to responsible owners and their dogs is therefore relatively cheap and effective. Microchipping a dog should infer legal ownership and reinforces the responsibilities of the owner under the Animal Welfare Act. The introduction of compulsory microchipping would allow stray dogs to be quickly returned to their owners, make easier the identification of owners who persistently allow their dogs to stray or cause nuisance, and make all puppies traceable to their breeder, helping to reduce the widespread problem of battery farming of dogs.

A new paper by D J Bartram and D S Baldwin, published in this week's Veterinary Record, has found that veterinary surgeons are four times as likely as the general public, and around twice as likely as other healthcare professionals, to die by suicide as opposed to other causes.

Professor Bill Reilly, President of the British Veterinary Association, said: "David Bartram's research in this difficult area is to be applauded. The more we can understand about the reasons behind the high suicide rate amongst veterinary surgeons, the more the BVA and other bodies can do to support vets in crisis.

"As part of the Vetlife Steering Group, the BVA supports fantastic initiatives such as the 24-hour Vet Helpline for vets, vet nurses and veterinary students, and the Veterinary Benevolent Fund.

"The BVA's Member Services Group (MSG) also spends a lot of time looking at practical initiatives to improve individual vets' day-to day lives. The recent introduction of the mediation and representation services to help resolve issues between veterinary employees and veterinary employers is a good example of the positive ways in which the BVA can support its members in difficult situations.

"The MSG also recently produced a helpline sticker for all veterinary practices to display on the medicines cabinet and other prominent places to act as a constant reminder that help is available.

"Ours is a small profession and many vets will know a friend or colleague who has taken their own life. It is essential that this issue is kept in the open so that those who are struggling know where to turn for help."

Genitrix has launched Libromide, the first licensed formulation of potassium bromide for the treatment of canine epilepsy, following what the company believes to be the largest ever trial of dogs suffering from epilepsy.

Genitrix says the availability, for the first time, of a licensed formulation of potassium bromide should give veterinary surgeons and pet owners the reassurance that the rigorous authorisation process provides.  It ensures, for instance, that the product has been developed especially for dogs and that it is manufactured in accordance with EU regulations. It also ensures that the product has been extensively and independently trialled, proven to be efficacious without adverse reactions, and that the necessary pharmacovigilance is in place to support it.  

The company also says that the availability of a licensed product paves the way for more comprehensive information to be provided to veterinary surgeons on the use of potassium bromide in treating seizures.  The Veterinary Medicines Directorate (VMD) imposes restrictions on educational materials supplied by manufacturers of unlicensed products, an approach which has created a 'knowledge gap' among many veterinary surgeons in general practice, according to some canine epilepsy experts.

Libromide tablets are intended for use in epileptic dogs which have already commenced therapy with Phenobarbital. Phenobarbital acts to increase the effects of the GABA inhibitory neurotransmitter in the central nervous system.  Potassium bromide is synergistic with Phenobarbital and raises the seizure threshold level in epileptic dogs. 

Libromide is classified as POM-V and will be available in 325 mg tablets in packs of 100 and 500 tablets.

Rodolfo Cappello DVM PhD DipECVN MRCVS, RCVS and European Specialist in Neurology and Neurosurgery, Head of Neurology Services at North Downs Specialist Referrals, Surrey, said: "I've been successfully using potassium bromide for the treatment of epilepsy in dogs for over 15 years.  The main problem has been that it's not been licensed as a medicine.  With the launch of Libromide, potassium bromide finally achieves the status of an approved pharmaceutical.  We will now be able to monitor quality, efficacy and side effects which will enable us to offer a more professional approach to the treatment of seizures."

Howard Wilder, founder and managing director of Genitrix, added:  "Canine epilepsy is an all too common disease with estimates suggesting it affects four in every hundred dogs in the UK.  It's also an illness which is not well enough understood with the lack of up to date information available to veterinary surgeons being a contributing factor.

We felt there was an opportunity to bring a licensed product to market and have invested hundreds of thousands of pounds in the process of development and trialling Libromide.  We're delighted to make it available to veterinary professionals and hope its launch will be the first step in improving treatment approaches for this distressing disease."

Novartis Animal Health has launched Zolvix, billed as the first truly novel anthelmintic class for livestock to be launched in more than 25 years, together with a new drenching system designed to make drenching faster, easier and more accurate.

Zolvix contains a new active ingredient, monepantel, which kills all key sheep gastro-intestinal nematodes (roundworms), including those resistant to the existing treatments.

According to the company, the development of this new drench follows the persistent challenge from worms that have developed resistance to the three other classes of drench - white (benzimidazole or 1-BZ), yellow (levamisole or 2-LV) and clear (macrocyclic lactone or 3-ML) and combinations of these. Zolvix has a unique mode of action and so forms a fourth generation of anthelmintic, which will be known as the 4- AD, or orange drench class

Novartis Animal Health has prioritised the UK and Ireland as key launch countries for Zolvix to provide their sheep farmers with an answer to the pressing challenge of increasing anthelmintic resistance.

Lesley Stubbings, an Independent sheep consultant and Sustainable Control of Parasites in Sheep (SCOPS) panel member, said: "Resistance has become an ever increasing threat since the last new anthelmintic group was introduced to the UK market more than 25 years ago. Zolvix offers farmers a valuable opportunity to maintain good worm control and prolong the effective life of the existing products. Following the SCOPS guidelines to carefully integrate Zolvix into worm control strategies, before the other groups fail, will allow our sheep industry to reap the full benefits of this new novel group."

A study carried out by Novartis in conjunction with the Hopkirk Research Institute showed that Zolvix treated sheep gained 33.5%, or 2.8 kg deadweight, more than sheep treated with a drench to which they were resistant.

Novartis Animal Health Brand Manager Simon Harris said: "Parasite resistance is a growing problem that decreases the productivity of sheep of all ages. Many veterinarians and farmers are concerned about this, with an increasing number of farmers reporting resistance to the three groups of wormers that have been available up to now, so the introduction of Zolvix is very timely."

At the same time, the company has also launched an award-winning new drenching system designed to offer 'a superior drenching experience for both animal and operator'. The new Optiline Drencher and Optivix backpack system were developed in collaboration with drenching specialists Simcro Tech Ltd.

The Optiline Drencher has already won several design and engineering awards, including a bronze award in the 2009 NZ BEST design awards, a coveted International Forum (IF) 2010 product design award from Germany and the prestigious Bayer Innovators Award for design and engineering.

It was also a finalist in the New Zealand Agritech Innovation Awards reached the finals in three categories of the 2009 New Zealand Trade and Enterprise International Business Awards.

The Optiline drencher is coupled with a durable, light Optivix backpack that has been specially tailored to provide left or right-handed operators with the same wide range of adjustment. It also has two drench cradles - at chest and hip level - to ensure maximum comfort.

Mr Harris said: "This drencher is best appreciated during use. Contact your local Novartis Animal health representative to arrange a trial."

Hill's Pet Nutrition has highlighted recent studies which, the company says, prove that feeding a food enriched with omega-3 fatty acids from fish oils to dogs with osteoarthritis results in a reduction in NSAID dosage of up to 25%¹, owner observed improvements in clinical signs³, and improved weight bearing ability^{2, 7}

The claim that food can effectively support medical treatment follows in the wake of two published and one in press study in the Journal of the American Veterinary Medicine Association (JAVMA). These demonstrate that omega-3 enriched food (in this case Hill's Prescription Diet j/d Canine) has significant  effects on weight bearing and helps reduce NSAID dosage by up to 25 per cent, when fed to dogs with osteoarthritis ^{1, 2,3}. 

According to Hill's, the research demonstrates that in dogs the high levels of eicosapentaenoic acid (EPA) from fish oils can down-regulate the cartilage degrading enzyme aggrecanase¹. In vitro studies have also identified that EPA resulted in a reduction in the amount of degraded cartilage residue produced⁴. High levels of omega-3 fatty acids can also help to reduce inflammation^5,6.

The two studies that were recently published confirm that feeding a diet rich in omega-3 fatty acids aids in the management of osteoarthritis in dogs^2,3. The randomized double-blinded controlled trials were carried out over three and six months respectively and involved a total of 165 dogs identified as suffering from mild to moderate osteoarthritis. After collating the results from almost 25,000 trial days, researchers were able to confirm a significant 'clinical improvement' from feeding a food fortified with fatty acids.

In the first study described in JAVMA, researchers found evidence that omega-3 fatty acids from fish oils resulted in improvements in weight bearing². Objective measurement using force plate gait analysis demonstrated that dogs fed a test food fortified with fatty acids were seven times as likely to show improved weight bearing compared with dogs fed a control food.

In the second study, through a detailed questionnaire, owners also observed significant improvements in their dog's osteoarthritic condition³.  Improvements observed covered the following signs: difficulty in rising from rest, limping, stiffness, soreness when touched, yelping or whimpering in pain, aggression, lagging on walks, reluctance to play and overall activity level.

Adrian Pratt, Veterinary Affairs Manager for Hill's Pet Nutrition, manufacturer of Prescription Diet j/d, which is enriched with omega-3 fatty acids, hailed the results as a breakthrough in the field of nutrigenomics (the study of the effects of nutrition on gene expression): "This research points the way to a new model for the management of osteoarthritis, using a clinically proven food to interrupt the cycle of damage and cartilage degradation, alongside graded levels of NSAIDs and proactive programmes to manage weight and adjust exercise routines. Clinicians now have the conclusive proof they need to recommend feeding omega-3 enriched food to ameliorate the signs of osteoarthritis in clients' pets and to adjust NSAID doses accordingly." 

For further information on Hill's Prescription Diet j/d, please contact your Hill's Territory Manager or call 0800 282438.

References
1. A multicenter study of the effect of a therapeutic food supplemented with fish oil omega-3 fatty acids on the Carpofen dosage in dogs with osteoarthritis. Fritsch A, Allen T, Dodd C, JAVMA in press
2. Evaluation of the effects of dietary supplementation with fish oil omega-3 fatty acids on weight bearing in dogs. Roush J, Cross A, Renberg W, Dodd C, Sixby K, Fritsch A, Allen T, Jewell, Richardson D, Leventhal P, Hahn K, JAVMA Vol 236 No 1, Jan 2010 pp67-73
3. Multicenter veterinary practice assessment of the effects of omega-3 fatty acids on osteoarthritis in dogs. Roush J, Dodd C, Fritsch A, Allen T, Jewell D, Schoenherr W, Richardson D, Leventhal P, Hahn K, JAVMA Vol 236 No 1, Jan 2010 pp 59-66
4. Eicosapentaenoate supplementation abrogates canine articular cartilage degeneration in in vitro explant culture systems, Caterson B, Cramp J, Little C B et al, Hills European Symposium on osteoarthritis and joint health 2005 14-19
5.  Dietary modification of inflammation with lipids, P C Calder, Proceedings of the Nutrition Society 2002 345-358
6.  Dietary polyunsaturated fatty acids and inflammatory mediator production, James M J, Cleland L G, Gibson R A, Am J Clin Nut 2000: 71 suppl 343S- 358S
7.  Vasseur PB, Johnson AL, Budsberg SC, et al. Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal anti-inflammatory drug, in the treatment of osteoarthritis in dogs. J Am Vet Med Assoc 1995; 206 (6): 807-811.

Following a five-year review of the Practice Standards Scheme, new standards will take effect from 1 April 2010, and be formally launched at the British Small Animal Veterinary Association Congress in Birmingham (8-11 April).

The Scheme, to which around 50% of practice premises are now signed up, exists to raise standards for the benefit of the public, as well as employees. The review was undertaken by the Practice Standards Group, which includes representatives from all of the key veterinary and veterinary nursing organisations. Its objective was to ensure that standards remain relevant and achievable, while representing better practice. The Group took on board improvements in practice over the last five years, and feedback from inspectors and practices.

Practice Standards Group Chairman, Jill Nute said: "It was important that the Group took account of what the public might reasonably expect of a well-equipped, professional practice. We have made some adjustments to the original standards, placing greater emphasis on clinical outcomes and training."

She added: "To ensure the Scheme goes beyond a 'box-ticking exercise', the emphasis for inspectors has moved towards assessing how standards are applied. For example, not just noting whether a protocol exists for the servicing of anaesthetic equipment, but asking staff involved how this is carried out and what checks are made on a daily basis to ensure the equipment is satisfactory."

The numbered 'tiers' have gone, as these were shown to be confusing. The descriptive categories (Core, GP, Hospital), together with differentiations (equine, small animal, farm animal, emergency services clinic), remain. In addition, to encourage more farm animal practices into the Scheme at GP level, 'where applicable' has been added to certain GP standards, so that those without small animal or equine facilities can comply.

There are some new standards - such as the requirement for annual appraisal systems for all clinical staff. In other cases, as expectations of better practice increase, standards that were previously for Hospitals must now be met by General Practices, and some of those for GPs now apply across the board.

Another change has been in the Manual (see www.rcvs.org.uk/newPSSmanual), which now incorporates guidance alongside the standards rather than in a separate document. The new format clarifies the derivation of each standard, so that legislative requirements are distinguished from those required under the RCVS Guide to Professional Conduct and those indicated by better practice.

Practices already on the Scheme will be given plenty of time to comply.

Visit stand 911 at BSAVA Congress for more information, or attend Hall 6 at 3.30pm on Saturday 10 April for a presentation on the changes.

Rabbit Awareness Week (26^th April - 2^nd May 2010) is reportedly going to be bigger than ever this year with over 1000 vets within the industry expected to be involved.

In partnership with Burgess Pet Care, Petplan Insurance, Company of Animals, Intervet/Schering-Plough Animal Health, Genitrix, PDSA, Wood Green Animal Shelters and RWAF, Rabbit Awareness Week's mission is to educate current and potential rabbit owners across the UK about the importance of rabbit welfare.

The focus of the week will be rabbit obesity. At the same time, organisers hope the week will raise the profile of rabbits as pets and encourage owners to seek the right veterinary advice about rabbit nutrition and health.

The week has been deliberately timed to happen soon after Easter, to make use of a time of year when rabbits are at the forefront of people's minds. Organisers hope to reach rabbit owners who may have bought new pet rabbits but who may not have the right information about how to keep them happy and healthy.

Throughout the week some of the UK's largest retailers, suppliers of rabbit food and welfare charities will be providing valuable feeding knowledge and information, along with a range of deals and offers to vets and pet owners. 

Organisers are asking veterinary practices to get involved by offering Free Health Checks for pet rabbits, and by providing free advice about vaccinations, husbandry and diet. To help, there is a range of display and training materials to help you run your Free Health Checks together with promotional materials such as newsletter templates and press releases. You can also register your event for free on the Online Event Locator.

The display kit includes shelf wobblers, barkers, posters, appointment flyers, Health Check Certificates and an A3 size Free Health Check window sticker. You'll also receive additional items to give away to rabbit owners, including Excel samples, RAW care guides, car stickers and branded bags.

For more information and to find out what special trade offers are available to vets during the week register at http://www.rabbitawarenessweek.co.uk/.

The Government has been forced to scrap plans for compulsory dog insurance less than a two weeks since they were revealed in leaked Defra documents.

Environment Secretary Hilary Benn has now ruled out the idea.

Apparently, the climbdown followed protests that compulsory insurance was no more than a 'dog tax' which would do nothing to curb the problem of dangerous dogs.

There's a certain irony in the way the story was reported in The Sun newspaper, with the headline: 'Labour forced to ditch pet plan'.

Indeed!

CEVA Animal Health has launched Marbokem, a Marbofloxacin-based antimicrobial for the treatment of respiratory disease in cattle which offers the advantages of a one-shot protocol and a shock-resistant vial.

Marbokem is used for the treatment of respiratory infections caused by sensitive strains of Pasteurella multocida, Mannheimia haemolytica and Histophilus somni. CEVA says Marbofloxacin's efficacy has been proven in terms of re-treatment rate, success, speed of action and MICs in comparison with many frequently used quinolones and macrolides. ^(1,2,3,4)

According to CEVA, Marbokem's one shot protocol means it's quick and economical to use, while its presentation in an ergonomic CLAS vial makes for light and shock-resistant handling, resulting in fewer breakages and reduced costs. The company says Marbokem is also very competitively priced.

For further product information, please contact CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/

¹ Grandemange, E., Fournel, S., Woerhle, F. (2009) Field evaluation of the efficacy of 2 antibiotics in treating bovine respiratory infections. Poster, Journées Nationales des GTV, Nantes, France.
^2. Grobbel, M., Lübke-Becker, A., Wieler, L., Froyman R., Friederichs, S., Filios, S. (2007) Comparative quantification of the in-vitro activity of veterinary fluoroquinolones. Veterinary microbiology 124 (73-81).
^3. Roy, O., Pillet, F., Heurtin-Vallé, A., Frontczak, N. (2008) Comparative field clinical efficacy of a single intramuscular injection of marbofloxacin in the treatment of bovine respiratory disease. Poster, World Buiatrics Congress, Budapest, Hungary.
^4. Wu, C. (2004) Determination of minimum inhibitory concentrations of danofloxacin and other commonly used cattle antimicrobial agents against Mycoplasma bovis isolated from cattle with clinical disease. Le médecin vétérinaire du Québec. 34 (1-2).